Advanced Gastric Cancer Treated by Endostar Combined with FOLFOX4 Therapeutic Schedule

XU Jian-zhong,XU Zhen,LING Yang
DOI: https://doi.org/10.3969/j.issn.1674-2257.2012.02.014
2012-01-01
Abstract:Objective To evaluate the efficacy and toxicity of endostar combined with FOLFOX4 in advanced gastric cancer.Methods Between July,2006 and March,2011,32 patients with advanced gastric cancer were received two-weekly endostar combined with FOLFOX4(Endostar 7.5 mg/m2 d1~7+L-OHP 85 mg/m2 iv.d1+CF200 mg/m2 iv.d1,d2 +5-Fu 400 mg/m2 iv.(bolus)d1,2+5-Fu 600 mg/m2 iv.d1,d2)at least for weeks.Results We observed 31 assessable patients,2 cases received CR,15 cases received PR,11 cases received SD,OR was 54.8%.The PFS was 7.4 months.The median survival period was 13 months.The one,three year survival rate were 51.6% and 16.1%,respectively.The major toxicities were neutropenia(69.7%),nausea and vomiting(56.2%),peripheral neuropathy(69.7%),mainly with 1~2 levels.Conclusion The therapeutic schedule of endostar combined with FOLFOX4 is effective and well tolerated.
What problem does this paper attempt to address?